Rossella Pellegrino

Dr. Rossella Pellegrino

Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2024 in Journal of Hepatology
Verified
Journal Article
Open access
MCMirco Castoldi
Mirco Castoldi
SRSanchari Roy
Sanchari Roy
CACarolin Angendohr
Carolin Angendohr
RPRossella Pellegrino
Rossella Pellegrino
MVMihael Vucur
Mihael Vucur
TLTom Lüdde
Tom Lüdde
In hepatocellular carcinoma (HCC), successful translation of experimental targets identified in mouse models to human patients has proven challenging. In this study, we used a comprehensive transcriptomic approach in mice to identify novel potential targets for therapeutic intervention in humans. We analyzed combined genome-wide miRNA and mRNA expression data in three pathogenically distinct mouse models of liver cancer. Effects of target genes on hepatoma cell fitness were evaluated by proliferation, survival and motility assays. TCGA and GEO databases, in combination with tissue microarrays, were used to validate the mouse targets and their impact on human HCC prognosis. Finally, the functional effects of the identified targets on tumorigenesis and tumor therapy were tested in hydrodynamic tail vein injection-based preclinical HCC models in vivo. The expression of miR-107 was found to be significantly reduced in mouse models of liver tumors of various etiologies and in cohorts of humans with HCC. Overexpression of miR-107 or inhibition of its novel target kinesin family member 23 (Kif23) significantly reduced proliferation by interfering with cytokinesis, thereby controlling survival and motility of mouse and human hepatoma cells. In humans, KIF23 expression was found to be a prognostic marker in liver cancer, with high expression associated with poor prognosis. Hydrodynamic tail vein injection of vectors carrying either pre-miR-107 or anti-Kif23 shRNA inhibited the development of highly aggressive c-Myc-NRAS-induced liver cancers in mice. Disruption of the miR-107/Kif23 axis inhibited hepatoma cell proliferation in vitro and prevented oncogene-induced liver cancer development in vivo, offering a novel potential avenue for the treatment of HCC in humans. Our study revealed the central role of the miR-107/KIF23 axis in controlling tumor cell fitness and hepatocellular carcinoma progression. The results demonstrate that the overexpression of miR-107 or silencing of its target, KIF23, markedly suppresses the proliferation, survival, and motility of human and mouse hepatoma cells. In this work, we demonstrate that the disruption of miR-107/Kif23 signaling effectively protects mice from an aggressive form of oncogene-induced liver cancer in vivo, implying that targeting miR-107/KIF23 might be a novel therapeutic approach for hepatocellular carcinoma in humans.

8 January 2021 in Cancers
Verified
Journal Article
Open access
PDF file
RPRossella Pellegrino
Rossella Pellegrino
ATAbhishek Thavamani
Abhishek Thavamani
DCDiego Francesco Calvisi
Diego Francesco Calvisi
JBJan Budczies
Jan Budczies
ANAriane Neumann
Ariane Neumann
TLThomas Longerich
Thomas Longerich
Different molecular mechanisms support the overexpression of the mouse double minute homolog 4 (MDM4), a functional p53 inhibitor, in human hepatocellular carcinoma (HCC). However, the transcription factors (TFs) leading to its transcriptional upregulation remain unknown. Following promoter and gene expression analyses, putative TFs were investigated using gene-specific siRNAs, cDNAs, luciferase reporter assays, chromatin immunoprecipitation, and XI-011 drug treatment in vitro. Additionally, MDM4 expression was investigated in SRF-VP16iHep transgenic mice. We observed a copy-number-independent upregulation of MDM4 in human HCCs. Serum response factor (SRF), ELK1 and ELK4 were identified as TFs activating MDM4 transcription. While SRF was constitutively detected in TF complexes at the MDM4 promoter, presence of ELK1 and ELK4 was cell-type dependent. Furthermore, MDM4 was upregulated in SRF-VP16-driven murine liver tumors. The pharmacological inhibitor XI-011 exhibited anti-MDM4 activity by downregulating the TFs driving MDM4 transcription, which decreased HCC cell viability and increased apoptosis. In conclusion, SRF drives transcriptional MDM4 upregulation in HCC, acting in concert with either ELK1 or ELK4. The transcriptional regulation of MDM4 may be a promising target for precision oncology of human HCC, as XI-011 treatment exerts anti-MDM4 activity independent from the MDM4 copy number and the p53 status.

3 May 2022 in Cells
Verified
Journal Article
Open access
PDF file
RPRossella Pellegrino
Rossella Pellegrino
MCMirco Castoldi
Mirco Castoldi
FTFabio Ticconi
Fabio Ticconi
BSBritta Skawran
Britta Skawran
JBJan Budczies
Jan Budczies
TLThomas Longerich
Thomas Longerich
Genomic and epigenomic studies revealed dysregulation of long non-coding RNAs in many cancer entities, including liver cancer. We identified an epigenetic mechanism leading to upregulation of the long intergenic non-coding RNA 152 (LINC00152) expression in human hepatocellular carcinoma (HCC). Here, we aimed to characterize a potential competing endogenous RNA (ceRNA) network, in which LINC00152 exerts oncogenic functions by sponging miRNAs, thereby affecting their target gene expression. Database and gene expression data of human HCC were integrated to develop a potential LINC00152-driven ceRNA in silico. RNA immunoprecipitation and luciferase assay were used to identify miRNA binding to LINC00152 in human HCC cells. Functionally active players in the ceRNA network were analyzed using gene editing, siRNA or miRNA mimic transfection, and expression vectors in vitro. RNA expression in human HCC in vivo was validated by RNA in situ hybridization. Let-7c-5p, miR-23a-3p, miR-125a-5p, miR-125b-5p, miR-143a-3p, miR-193-3p, and miR-195-5p were detected as new components of the potential LINC00152 ceRNA network in human HCC. LINC00152 was confirmed to sponge miR143a-3p in human HCC cell lines, thereby limiting its binding to their respective target genes, like KLC2. KLC2 was identified as a central mediator promoting pro-tumorigenic effects of LINC00152 overexpression in HCC cells. Furthermore, co-expression of LINC00152 and KLC2 was observed in human HCC cohorts and high KLC2 expression was associated with shorter patient survival. Functional assays demonstrated that KLC2 promoted cell proliferation, clonogenicity and migration in vitro. The LINC00152-miR-143a-3p-KLC2 axis may represent a therapeutic target in human HCC.

16 August 2023 in Cancers
Verified
Journal Article
Open access
PDF file
MPMartha Paluschinski
Martha Paluschinski
JSJessica Schira-Heinen
Jessica Schira-Heinen
RPRossella Pellegrino
Rossella Pellegrino
LHLara Heij
Lara Heij
JBJan Bednarsch
Jan Bednarsch
MCMirco Castoldi
Mirco Castoldi
MicroRNA miR-122 plays a pivotal role in liver function. Despite numerous studies investigating this miRNA, the global network of genes regulated by miR-122 and its contribution to the underlying pathophysiological mechanisms remain largely unknown. To gain a deeper understanding of miR-122 activity, we employed two complementary approaches. Firstly, through transcriptome analysis of polyribosome-bound RNAs, we discovered that miR-122 exhibits potential antagonistic effects on specific transcription factors known to be dysregulated in liver disease, including nuclear respiratory factor-1 (NRF1) and the E2F transcription factor 4 (E2F4). Secondly, through proteome analysis of hepatoma cells transfected with either miR-122 mimic or antagomir, we discovered changes in several proteins associated with increased malignancy. Interestingly, many of these proteins were reported to be transcriptionally regulated by NRF1 and E2F4, six of which we validated as miR-122 targets. Among these, a negative correlation was observed between miR-122 and glucose-6-phosphate dehydrogenase levels in the livers of patients with hepatitis B virus-associated hepatocellular carcinoma. This study provides novel insights into potential alterations of molecular pathway occurring at the early stages of liver disease, driven by the dysregulation of miR-122 and its associated genes.

1 July 2019
Verified
Conference Paper
Closed access
CPChristos Patsis
Christos Patsis
JCJoan Crous-Masó
Joan Crous-Masó
ISIlaria Salvato
Ilaria Salvato
LBLuise Butthof
Luise Butthof
RPRossella Pellegrino
Rossella Pellegrino
DTDarjus Tschaharganeh
Darjus Tschaharganeh
Hepatocellular carcinoma (HCC) represents the predominant primary liver malignancy and the second most common cause of cancer-related death worldwide. Although several advances have been made in HCC screening and diagnosis, the therapeutic treatment of advanced disease at present relies mainly on sorafenib and regorafenib, two multi-kinase inhibitors, which demonstrate limited clinical efficacy. Recently, several genomic studies have unveiled the underlying genomic changes governing HCC development, consisting of mutations in prominent driver genes, as well as copy-number variations (CNVs), such as amplifications and deletions of whole chromosome regions, which exceed by far the frequency of individual mutations. Interestingly, CNVs are considered to mediate clonal expansion due to the presence of oncogenic driver genes, but generally comprise also neutral bystander genes with no implication in neoplastic transformation. While current therapeutic approaches largely aim at targeting mutation-induced dysregulated pathways, strategies targeting CNVs are not thoroughly pursued. We hypothesized that passenger aberrations in genomic amplifications of tumor cells could be therapeutically exploited by providing actionable molecules on the cell surface. To this end, we performed bioinformatic analyses of TCGA CNV data and uncovered a list of cell surface protein (CSP) genes which are frequently amplified in HCC and could be used as potential candidates for a “Trojan-horse” approach in this tumor entity. More specifically, a set of CSP genes was found to be amplified in more than 60% of HCCs, as well as other solid tumors. Genetic perturbations of their expression levels had no effect on the growth and proliferation of HCC cell lines, suggesting their passenger status in the context of this malignancy. Furthermore, amplification of CSP-genes resulted in increased protein expression, which was localized primarily at the plasma membrane. Interestingly, a wide range of normal tissues displayed absent to low cytoplasmic levels of these CSPs as compared to several solid tumors, which exhibited diverse cell surface-associated expression. In addition, pharmacological inhibition of various oncogenic signaling pathways in cancer cells led to significant CSP upregulation at the protein level in the absence of respective genomic amplifications, raising the therapeutic prospect of targeting these proteins as second hits in combination drug regimens. In summary, we have identified several CSPs as potential targets in HCC, which could achieve high tumor specificity while sparing normal tissue when targeted by anti-CSP radioisotope-conjugated antibodies or CSP-specific CAR-T cells. Citation Format: Christos Patsis, Joan Crous-Masó, Ilaria Salvato, Luise Butthof, Rossella Pellegrino, Thomas Longerich, Matthias Gaida, Petros Christopoulos, Darjus Tschaharganeh. Therapeutic exploitation of passenger amplifications in hepatocellular carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4476.

13 January 2014 in Zeitschrift für Gastroenterologie
Verified
Journal Article
Closed access
RPRossella Pellegrino
Rossella Pellegrino
ATA Thavamani
A Thavamani
RGR Geffers
R Geffers
PSP Schirmacher
P Schirmacher
ANA Nordheim
A Nordheim
TLT Longerich
T Longerich
MDM 4 is a p53 binding protein that negatively regulates p53-dependent transcription. MDM 4 was found overexpressed in a variety of human cancers and amplifications of the MDM 4 gene locus were reported most of these tumor entities. We have previously demonstrated that MDM 4 is upregulated in about 50% of human hepatocellular carcinomas (HCC), both at messenger RNA (mRNA) and protein level. Although we identified 1q32 gains as a mechanism leading to MDM 4 overexpression in human HCC, many liver tumors display a balanced MDM 4 gene locus. Thus, additional mechanisms are responsible for aberrant MDM 4 expression in the presence of a diploid MDM 4 gene locus. The transcriptional regulation of MDM 4 remains largely elusive. Here, we show that overexpression of SRF is involved in the transcriptional upregulation of MDM 4 in HCC thereby supporting its protumorigenic function. Using in silico analysis we identified a putative SRF binding site in the MDM 4 promoter region. Overexpression of SRF mRNA compared to normal liver tissue was observed in a collection of human HCCs. In addition, a strong positive correlation between MDM 4 and SRF expression was found in these samples. To test our hypothesis that SRF might play a role in the regulation of MDM 4 expression, we treated HCC cell lines with specific siRNA targeting SRF resulting in a significant decrease of MDM 4 mRNA and protein levels and the re-activation of p53 target genes (e.g. PUMA, BAX and p21) in transfected HCC cell lines. Furthermore functional re-activation of p53 function was indicated by decreased cell viability following SRF knockdown. Finally, upregulation of MDM 4 was observed in SRF-VP16 transgenic mice in vivo. Taken together, our data demonstrate a crucial role of SRF in the transcriptional activation of MDM 4 expression, thereby supporting the oncogenic MDM 4 activity in HCC in vitro and in vivo.